Biologics and DMARDs Archives - ACR Meeting Abstracts

Abstract Number: 1805 • ACR/ARP Annual Meeting 2019
Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study
Marianne Kerski¹, Peter Boersma ², Eric Miller ³, Ashley Brenner ⁴, Genevieve Melton ⁵ and Anna Shmagel ⁶, ¹University of Minnesota Medical School, Minneapolis, MN, ²University of Minnesota School of Public Health, Minneapolis, ³University of Minnesota, Woodbury, MN, ⁴University of Minnesota Best Practices Integrated Informatics Core (BPIC), Minneapolis, MN, ⁵University of Minnesota Department of Surgery, Minneapolis, MN, ⁶University of Minnesota, Minneapolis, MN
Background/Purpose: Perioperative management of anti-rheumatic drugs in rheumatoid arthritis (RA) patients undergoing surgery remains controversial. Previous studies produced conflicting results, and data on non-orthopedic surgeries…
Abstract Number: 2343 • ACR/ARP Annual Meeting 2019
Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease
Shinji Watanabe¹, Takahisa Gono ¹, Ryosuke Fukue ¹, Seiji Kobayashi ¹, Yuichiro Shirai ², Mitsuhiro Takeno ³ and Masataka Kuwana ², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ³Nippon Medical School, Tokyo, Japan
Background/Purpose: Pulmonary complication is one of the leading causes of mortality in patients with rheumatoid arthritis (RA). Pre-existing lung disease is known as a risk…
Abstract Number: 2908 • ACR/ARP Annual Meeting 2019
Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study
Hanna Källmark¹, Jon Einarsson ², Jan-Åke Nilsson ³ and Meliha Kapetanovic ², ¹Lund University, Lund, Sweden, ²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ³Skane University Hospital, Lund and Malmö, Sweden, Lund, Sweden
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX),…

Abstracts tagged "Biologics and DMARDs"

Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study

Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease

Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study